cGMP Deviations
Drugs Recalls
Prescription and over-the-counter medications
cGMP Deviations
cGMP Deviations
cGMP deviations
cGMP deviations
cGMP deviations
Failed Impurities/Degradation Specifications and Subpotent Drug: High Out of Specification results for a known and unknown impurity as well as low Out of Specification results for assay.
cGMP deviations
cGMP deviations
cGMP deviations
cGMP deviations
CGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.
cGMP deviations
cGMP deviations
Lack of assurance of sterility: Suspected microbial growth present on external label packaging.
cGMP deviations
CGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.
cGMP deviations
Daytrana (methylphenidate transdermal system) CII, 30 mg, 30-count carton, Rx only, Manufactured for Noven Therapeutics, LLC., Miami by Noven Pharmaceuticals, Inc., NDC 68968-5555-3
Noven Pharmaceuticals
Defective Delivery System: Out of specification for shear.
JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA
Boehringer Ingelheim Pharmaceuticals
Labeling: Label Mix-up